Factor Bioscience Inc., a biotechnology company based in Cambridge, Massachusetts, is thrilled to announce the addition of three new members to its translational science team. Led by Kyle Garland, Ph.D., the team will focus on developing cutting-edge mRNA and cell-engineering technologies.
Dr. Garland, along with Associate Scientists Raven Hinkel and Elizabeth Belcher, brings a wealth of experience in translational research related to mRNA and cell engineering. Their expertise includes synthetic mRNA, mRNA cell reprogramming, gene editing, cell manufacturing, immunoengineering, and nucleic acid formulation.
Factor’s Co-Founder and Chief Technology Officer Dr. Christopher Rohde highlighted the diverse backgrounds of the new team members and their expertise in various scientific fields. The team aims to support strategic partnerships and drive the translation of technologies into new products that promote health and improve lives.
Dr. Garland expressed his excitement about joining Factor and working alongside Drs. Angel and Rohde to leverage the company’s foundational mRNA and cell-engineering technologies. He believes that these technologies have the potential to revolutionize biotechnology research and development, leading to the creation of innovative products that benefit humanity.
Prior to joining Factor, Dr. Garland led the Department of Research and Development at Eterna Therapeutics, overseeing preclinical programs and strategic collaborations. He holds a Ph
